Peter W. PENG, Author at MediaMedic

Dr. Taiyuan Li: NOSES Surgery – From “Minimally Invasive” to “Scarless” at the Chinese Medical Doctor Association’s Colorectal Oncology Committee

By Peter W. PENG 2025.03.17

The emergence and evolution of natural orifice specimen extraction surgery (NOSES) in colorectal oncology marks a significant milestone in the journey toward scarless surgery. Since Professor Xishan Wang’s team first…

SGBCC 2025 | Dr. Giuseppe Curigliano on Advancing Toward a Cure for Advanced Breast Cancer

By Peter W. PENG 2025.03.14

NHHR Shows Great Potential in Predicting MASLD in Obese and Type 2 Diabetes Populations

By Peter W. PENG 2025.03.12

Editor’s Note: Metabolic dysfunction-associated steatotic liver disease (MASLD) affects approximately one-quarter of the global adult population, imposing a significant health and economic burden. However, there are currently no approved treatments…

New Non-Invasive Screening Strategies Improve MASH Clinical Trials by Reducing Screening Failure Rates

By Peter W. PENG 2025.03.07

Editorial Note: Metabolic-associated steatohepatitis (MASH) is a subtype of metabolic-associated fatty liver disease (MASLD), characterized by hepatic steatosis, lobular inflammation, and hepatocellular ballooning, with a high risk of progressing to…

Professor Xichun Hu’s Team: Lerociclib plus letrozole versus placebo plus letrozole in HR+/HER2- advanced or metastatic breast cancer

By Peter W. PENG 2025.03.05

Editor's Note: The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting concluded successfully. At this conference, two studies from Professor Xichun Hu’s team at Fudan University Shanghai Cancer Hospital…

Research Progress丨Analysis of Platinum Intolerance and Treatment Outcomes in First-Line Treatment of Advanced Urothelial Carcinoma Patients

By Peter W. PENG 2025.02.28

Advanced urothelial carcinoma (UC) patients have a poor prognosis with a low 5-year survival rate. Since the 1980s, platinum-based chemotherapy has been the standard first-line therapy for locally advanced or metastatic UC (la/mUC), but the benefits are limited. The real-world tolerance and treatment outcomes of platinum therapy remain unclear. This year's study analyzed data from advanced UC patients in the United States. This article summarizes and organizes the findings for our readers.

ASCO GI 2025 | Dr. Anna Dorothea Wagner：Dual-Target Therapy Shows No Survival Benefit in HER2-Positive Gastric Cancer

By Peter W. PENG 2025.02.27

The 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI 2025) successfully concluded on January 25. One of the most closely watched presentations at the conference was the release of results from the EORTC-1203—INNOVATION trial (Abstract LBA331), capturing the attention of oncologists worldwide. Oncology Frontier had the exclusive opportunity to interview Dr. Anna Dorothea Wagner, a medical oncologist from Lausanne University Hospital in Switzerland, to discuss the study’s findings. Below is a summary of our conversation.

ASCO GI 2025 | Dr. Zhenyu Lin: Short-Course Radiotherapy Plus Targeted, Immuno-, and Chemotherapy for High-Risk LA

By Peter W. PENG 2025.02.25

Editor's Note: The neoadjuvant treatment landscape for locally advanced rectal cancer (LARC) continues to evolve, with emerging research indicating that incorporating immunotherapy can significantly enhance the pathological complete response (pCR)…

Advancing Early-Stage Breast Cancer Monitoring with ctDNA Structural Variant Detection

By Peter W. PENG 2025.02.25

A recent study published in Clinical Cancer Research (Jan 9, 2025) highlights the potential of structural variant (SV)-based circulating tumor DNA (ctDNA) detection in early-stage breast cancer (EBC). Unlike traditional…

ASCO GI 2025 | Dr. Xiufeng Liu’s In-Depth Analysis of CheckMate 9DW and CARES-310 Study Updates

By Peter W. PENG 2025.02.24

The landscape of systemic therapy for hepatocellular carcinoma (HCC) has undergone a major transformation, shifting from single-agent targeted or immunotherapies to dual immune checkpoint inhibitors and immune-targeted combination regimens. The 2025 ASCO Gastrointestinal Cancers Symposium (ASCO GI), held on January 23, 2025, highlighted two pivotal studies—CheckMate 9DW and CARES-310—focusing on dual immunotherapy strategies for previously untreated unresectable hepatocellular carcinoma (uHCC) and the impact of viral infection status on treatment outcomes.